The economic impact of weight regain.
Obesity has been established as a global economic burden. Several countries have already quantified the costs associated with obesity on their healthcare systems, and unequivocally bariatric surgery has been found to be a cost-effective method for reducing obesity related costs and increasing quality of life [1-4]. However, the literature has investigated neither the cost of procedure failure rate due to weight regain or insufficient weight loss, nor the cost burden of patients returning to their original obesity status.
The rate of weight regain has been reported as ranging from 5 to 39% corresponding to a median of 20% (average: 21.1% [+ or -] 10.1%, range: 5.2-39, n = 10) 5-14]. Several authors have attributed this phenomenon to mechanical failure, such as pouch and stoma dilation, while others believe that the behavioural component is the main contributor to weight gain over time [8,15,16]. Weight recidivism can be dealt with via two facets: the patient can remain obese or an attempt at surgical revision can be undertaken. Revision can include band removal, band replacement, conversion to sleeve gastrectomy or gastric bypass, gastric bypass limb lengthening, and endoscopic techniques, each of which has an associated cost and complication risk. Many institutions in the United States will have performed multiple revisions for their patients.
The objective of this study was to identify the revision rates of bariatric procedures and only the direct healthcare costs associated with weight recidivism by performing a literature search. This study does not intend to serve as a cost analysis of the impact revision which surgery has on bariatric surgery cost-effectiveness; indirect costs to society are not included.
2.1. Literature Search. A Medline search was performed in June 2013 with the assistance of a health librarian at the University of Alberta using search terms: bariatric surgery, revision, recidivism, cost-analysis, and economics. For a complete list of mesh terms see the appendices.
The preliminary search was performed to identify the cost of various bariatric surgeries, including revision procedures, and the rate of weight regain associated with these procedures. A total of 213 articles were identified. A secondary search was performed in July 2013 for articles with fail * or revision * in title along with the names of the major bariatric surgeries and limited to articles published between 2003 and 2013. This identified 198 articles. Articles were not included if they involved fundoplication, antireflux surgery, plastic surgery, revision of vertical banded gastroplasty (since it is no longer performed as a primary surgery), duplicate findings, revision of bariatric procedures due to complications such as ulcers, staple line failure, or hemorrhages, case studies, and revision of bariatric surgery due to hepatic or renal failure. The literature search was designed to investigate the data pertaining to the paradigm outlined in Figure 1.
2.2. Costing. Direct costs of obesity were included in this study from several countries and the literature available since 2000. Direct costs were identified using the definition described by Terranova et al., such that costs represented the costs of behavioural, pharmacological, and physician management of obesity associated comorbidities . Indirect costs, such as loss of work productivity, disability payments, and loss of productive years, were not included in the calculation of obesity. The Canadian studies were converted to 2013 CAD using the Bank of Canada inflation calculator based on monthly consumer price indexes determined by Statistics Canada .
The cost of primary bariatric surgery was provided by Alberta Health Services Financial Department. At our institution, 61 laparoscopic adjustable gastric bands (LAGB) from 2011 to 2012, 227 laparoscopic sleeve gastrectomies (LSG), and 187 laparoscopic Roux-en-Y gastric bypasses (LRYGB) were performed from 2010 to 2012 at a mean total cost of $10,470.90, $11,934.17, and $17,882.96, respectively. These costs are a summation of average direct costs (average costs of length of stay, supplies, staff, medications, equipment, ambulance transfers, and sundries) and indirect costs (administration and support costs for each clinical service). Complication costs were estimated based on the summation of direct procedure costs and multiplied by the rate of occurrence for each bariatric procedure. Complication costs were represented as the costs per complicated patient each year. The cost of receiving any of the three mentioned bariatric procedures plus complications was calculated. Patients also attend a median of nine visits with the Weight Wise clinic multidisciplinary team before surgery. The team includes physicians, psychologists, dieticians, nurses, psychiatrists, and surgeons, whom all contribute a cost.
A basic cost of revision was based on averages provided by the operating room at our institution. The cost of the bariatric revision team was included in this calculation for a median of four visits per patient. Only a range of complication costs was provided, due to an unidentified complication rate for revision surgeries. Surgeon billing was also included in this amount. The total cost of revision surgery is based on conservative costing; not all direct costs were available. Bariatric surgeries included in this calculation are gastroplasty reversal, stomach resection, open bariatric procedures, and bariatric reversals.
2.3. Analysis. The bariatric procedure failure rates due to weight recidivism, total revision rate, and revision rate due to weight recidivism or insufficient weight loss were averaged and presented as average [+ or -] standard deviation (number, range), or the median was used when appropriate.
3.1. Cost of Obesity. The quoted cost of obesity in Canada was $2.0 billion-$6.7 billion in 2013 CAD [18, 19]. Direct obesity expenditures were estimated to be 4.1% of total health expenditures in 2006 . Obesity costs in Alberta alone were reported to range from $109.9-$726.4 million in 2013 CAD [20,21]. In the United States, costs of obesity have been said to range from $98.1-209.7 billion in 2008, attributing to 20.6% of US national health expenditures [22,23]. Other nations, such as Australia, determined that direct costs were $2788 AUD per person per annum (2005) .
3.2. Cost of Primary Bariatric Surgery. At our institution, the average cost of LAGB, LSG, or LRYGB in a year was calculated to be $13,869.95. Additionally, complications included band removal, ulceration, hemorrhage, staple line leak, anastomotic stricture, and internal hernia. The median complication rate was 1.2% (average: 2.6% [+ or -] 3.3, range: 0.3%-8.9%), equivalent to a cost of $556.83 per complicated patient each year (range: $310.33-$4,208.20). In addition to the cost of procedure and complications, a patient will incur a cost of $495.86 for visits with the bariatric team. In total approximately $14,383.32 (range: $10,984.27-$18,396.33) was spent per patient per year. To our knowledge no other Canadian literature has published the cost of initial bariatric surgery. The American literature quotes bariatric surgery to cost anywhere from $14,000 to $24,000 for all procedures [1,2,25].
3.3. Rate of Primary Revision. A review of the literature was performed, and 36 articles contained information on the failure rate of bariatric procedures due to weight gain/insufficient weight loss or primary and secondary revision rates (Table 1). The median percentage of bariatric procedures that fail due to weight gain or insufficient weight loss is a median of 20% (average: 21.1% [+ or -] 10.1%, range: 5.2-39, n = 10), and a mean of 22 [+ or -] 10 kg of regained weight between 1 and 52 months [5-14]. The rates of revision can be found in Figure 2 [5, 9, 10, 13, 14, 26-46]. The average of a second bariatric revision surgery ranges from 20.0% to 25.2%, and 13.0% to 25.0% due to weight gain [5,13, 34, 41].
The average timeframe from primary bariatric procedure to revision was 35.4 [+ or -] 13.4 months (range: 4 days-120 months, n = 13) 5, 9,10,13,14, 26, 27, 33, 39, 41-43, 47]. The rate of patients that regained weight but did not receive surgery or were not surgical candidates could not be identified from the literature. These patients may incur healthcare costs similar to being originally obese with comorbidities. Tucker et al. reported that 22% of revision patients required intervention due to either comorbidity recurrence or nonresolution . In addition, procedures such as LAGB have immense variation in success with reducing or resolving comorbidities (28.6%-100%) such as type 2 diabetes, sleep apnea, and hypertension . Failed LSG has a range of comorbidity prevalence in revision patients between 11% and 56% . The costs of an obese individual with comorbidities have been identified in the Canadian literature between $600 and $1,200 per person per annum in 2013 CAD for physician costs and hospitalization [49, 50]. The American literature reports $1,700 and $2,700 in 2008 and 2005 USD, respectively [22, 23].
After revision surgery, patient's excess weight loss was 48.7%-50% after 2 years and an average of 15.2 kg lost after 1-52 months [14,43,51]. While not performed at our institution, LRYGB revision by limb lengthening has been reported to improve weight loss with an EWL from 26.6% to 60.9% 1 year postrevision and 68.8% after 5 years [52, 53].
Complication rates for revision surgery have been reported as either equivalent to primary bariatric surgery 29.6% versus 30.9% [31, 41, 43] or significantly higher. These complications included band slippage and erosion, hernia, infection, abdominal abscess, gastric emptying, anastomotic leak, strictures and ulcers, and weight loss failure. The average complication rate for all revision procedures ranged from 5.5% to 19.4% [5, 10, 13, 33, 35, 44, 45, 54]. More complex revision procedures such as biliopancreatic diversion have higher rates of complications of 25.3% . These complication rates were also associated with longer average length of hospital stay, 2.8-3.6 days, and 8.2 days for a second revision [13, 35, 44].
3.4. Cost of Revision. The average surgical cost of bariatric revision at our institution is $5,624.00. Gastric band removal ranges from $895 to $1,223. Surgeon billing depending on the procedure can vary from $889.60 to $2,930.59. The cost of complications may vary from investigating ulcers and anastomotic leaks ($19760-$228.82) to a laparotomy ($120-$650). Hospital stay is $1,483 per night or $3,178 per night in the intensive care unit (ICU). The bariatric team costs $218.18 per patient for a median of 4 visits. A total cost at our institution for bariatric revision surgery can be approximated to range from $3,485.78 to $12,617.59 CAD.
From the literature and as would be expected, a greater hospital cost was incurred by revision surgery than by primary bariatric surgery. For gastric banding a difference of $4,147 in hospital costs ($14,153 [+ or -] $14,227 versus $10,004 [+ or -] $4749, 2011 USD) and LRYGB incurs a difference of $13,257 ($35,189 versus $49,377) [35, 44]. These do not include the cost of an interdisciplinary team or costs incurred by complications.
Thirty-six articles were found with information on bariatric revision rates. Causes of revision surgery may vary from gastric stoma dilation to lack of follow-up with the bariatric team (60%-80% of patients) . The majority of these articles focused on gastric band revision, which was reported as having an increased number of reoperations, rising nearly 2-fold from 2005 to 2008 in the United States . The literature pertaining to revision rates is sparse for LSG or LRYGB revision. While the cost of obesity has been thoroughly researched, there was a paucity of the literature on the cost of these reoperations. Furthermore the costs elicited were from American sources, limiting the ability to extrapolate Canadian costs for revision.
Regardless of nationality, obesity comprises a substantial amount of the countries' healthcare expenditures. In addition, Peeters et al. reported that life expectancy of obese men and women is decreased by 5.8 and 7.1 years, respectively . A costly component is bariatric surgery yet it is considered the most successful treatment for this disease . In Canada alone, estimated 1100-1200 bariatric surgeries are performed every year . The cost of bariatric surgery has been well established as a long term cost-effective method for treating obesity due to the reduction in comorbidity management costs, despite a front loaded cost of $14,000-$24,000. The cost estimates calculated at our institution and within the literature are similar.
An 18%, 58%, and 82% reduction in obesity related costs could be observed at 12 months, 13-24 months, and 25-36 months after bariatric surgery, respectively . Monk et al. reported cost savings of $182.10 a month in pharmaceutical use 6 months postop ($317.30 preop versus $135.20 postop, in 2004 USD) . Cost-effectiveness is measured by determining the incremental cost-effectiveness ratio, which contrasts incremental costs with incremental health benefits (increased years of life). A lower incremental cost-effectiveness ratio indicates that the same unit of outcome can be achieved at a lower cost . The Canadian Agency for Drugs and Technologies in Heath (CADTH) determined that all primary bariatric procedures corresponded with an incremental cost-utility ratio ranging from $6,500 to $12,000 per additional quality-adjusted life years (QALY), compared to nonsurgical treatment over a life span . These calculations included revision surgery as part of the complications of surgery occurring within one year postop, not weight recidivism, and were based on merging the cost-effectiveness of bariatric surgery found in several articles. The literature from the United States is similar to an incremental cost-effectiveness ratio of $6,600 per QALY for LRYGB and $6,200 for LAGB . Cost savings of $900 USD per month can be seen as early as 13 months postop from laparoscopic bariatric surgery (in 2008) . These cost savings account for a reduction in two-thirds of medical expenses associated with obesity .
Revision surgery has not been taken into account when calculating these cost savings. The rate of weight recidivism uncovered in the literature is approximately equivalent to our institution's estimated rate of 10-20%. There are several types of revision procedures that are performed when weight loss is unsuccessful. Revision of a primary surgery on average ranges from 2.5% to 18.4%, and depending on the procedure accounts for an additional cost of $14,000-$50,000. It is projected that our institution would incur a similar cost due to revision. This accounts for a substantial cost to the system and does not include the cost of complications, the cost of subsequent revisions (20.0%-25.2%), or continuing in a bariatric intervention program. The rate of complications has been predominantly reported as being significantly higher than primary bariatric surgery (5.5%-19.4%) and would indicate that the cost of complications would also be greater. While complication rates vary between procedures, according to the CADTH, AGB has been recognized as requiring procedure reversals or conversions more often than RYGB, regardless of the decreased risk of anastomotic ulceration, stricture, or hernia . However, the time from the primary surgery to revision plays a role in decreasing costs if the patient was successful in losing weight due to the primary surgery. A discount rate applies to the expected rate of revision, to allow for a decrease in costs by 5% each year of successful weight loss . This would correspond to a 5% reduction in costs for the average of 2.9 [+ or -] 1.1 years (35.4 [+ or -] 13.4 months) until revision is required.
While not performed at our institution, there are several endoscopic revision treatments, such as sclerotherapy, Bard EndoCinch Suturing system, Incisionless Operating Platform, StomaphyX, OverStitch, OTSC-Clip, and sodium morrhuate, and more complex procedures, such as the biliopancreatic diversion with or without duodenal switch (BPD-DS) that incur another cost on the healthcare system [15, 61]. In particular, BPD-DS has been noted to have a complication rate of 25% as a revision procedure and requires an expert skill set to perform.
Given that the literature of the revision rates is not Canadian, it would not be accurate to apply Canadian costing to revision rates that would be expected to be for a substantially larger influx of bariatric patients per year at an American institution. Our institution is budgeted for approximately 250 bariatric procedures a year and an additional 35 of these spots corresponding to revision patients from our institution and others. Due to these barriers, we are not in a position to present accurate cost analysis of Canadian bariatric surgery.
Revision surgery is successful in achieving weight loss even following initial weight recidivism , which may factor in overall cost savings. However, no literature exists on the cost of patients who return to their initial weight with comorbidities and are either not willing to have another operation or are not revision candidates. How this weight recidivism plays into the economic analysis of bariatric surgery and societal obesity costs has not yet been investigated to our knowledge.
All of the branches of Figure 1 encompass costs, not simply to the healthcare system but to society as a whole. Despite the amount of funding and research available for bariatric surgery, a paucity exists in the bariatric revision literature. Reoperations represent a substantial cost to the healthcare system and should be incorporated into cost-benefit analysis for bariatric surgery to obtain accurate data for this treatment.
In summary, when making a commitment to offer bariatric surgery services, costs need to account for an inevitable proportion of patients who will fail in primary surgery and will need a multitude of additional strategies to deal with their weight recidivism/regain. These range from simple diet/lifestyle interventions through to endoscopic manoeuvers and significantly major revisional surgery. Consequently, a significant dearth of information exists regarding these inevitable costs. Directions will be taken to calculate the revision rate at our institution and the associated costs.
A. Preliminary Search June 28, 2013
(1) exp Bariatric Surgery/
(2) (bariatric surgery or LAGB or gastric band * or lap band * or lap-band * or lapband* or roux-en-y or vertical sleeve or sleeve gastrectom * or gastric bypass * or jejuno-ileal bypass* or Jejunoilea* bypass *).mp.
(3) Obesity, Morbid/su [Surgery]
(4) 1 or 2 or 3
(7) (regain * or recidivism).tw.
(8) ((weight or pounds or lbs or kgs or kilograms or percent *) adj6 (gain or gained)).tw.
(9) Weight Gain/
(10) 5 or 6 or 7 or 8 or 9
(11) 4 and 10
(12) exp "Costs and Cost Analysis"/
(13) (cost * or economic * or expenditures or price or fiscal or financial or burden or efficiency or pay or valuation or pharmacoeconomic or spending).ti.
(14) (economic adj1 (evaluat * or analys * or study or studies or assess* or consequence *)).tw.
(15) (cost-benefit or benefit-cost or cost effectiv * or cost utility).tw.
(16) (cost minimization or cost minimisation or cost consequence* or cost offset *).tw.
(17) ((cost or costs) adj2 analys *).tw.
(18) "cost of illness".tw.
(20) 11 and 19
(21) (surgery or bypass or sleeve or band * or lap-band or plicaton or roux-en-y).ti.
(22) (gain or gained or regain* or recidivism or revision * or fail * or reoperation).ti.
(23) pregnan * .ti.
(24) (11 and 21 and 22) not 23 (213 articles).
B. Secondary Search July 15, 2013
(1) exp Bariatric Surgery/
(2) (bariatric surgery or LAGB or gastric band * or lap band * or lap-band * or lapband * or roux-en-y or vertical sleeve or sleeve gastrectom* or gastric bypass * or jejuno-ileal bypass * or Jejunoilea * bypass *).mp.
(3) Obesity, Morbid/su [Surgery]
(4) 1 or 2 or 3
(5) 4 and (revision or (fail * not (heart fail * or liver fail * or respiratory fail * or renal fail * or hepatic fail * or kidney fail *))).ti.
(6) limit 5toyr = "2003-2014"
Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.
Both Dr. Daniel W. Birch and Dr. Christopher J. de Gara receive financial contributions from Ethicon Johnson & Johnson to use their surgical equipment; however, this is unrelated to the publication at hand.
 B. Wang, E. Wong, R. Alfonso-Cristancho et al., "Cost-effectiveness of bariatric surgical procedures for the treatment of severeobesity," European Journal of Health Economy. In press.
 P.-Y. Cremieux, H. Buchwald, S. A. Shikora, A. Ghosh, H. E. Yang, and M. Buessing, "A study on the economic impact of bariatric surgery," American Journal of Managed Care, vol. 14, no. 9, pp. 589-596, 2008.
 L. Terranova, L. Busetto, A. Vestri, and M. Zappa, "Bariatric surgery: cost-effectiveness and budget impact," Obesity Surgery, vol. 22, pp. 646-653, 2012.
 J. S. Sampalis, M. Liberman, S. Auger, and N. V Christou, "The impact of weight reduction surgery on health-care costs in morbidly obese patients," Obesity Surgery, vol. 14, no. 7, pp. 939-947, 2004.
 A. Ardestani, D. B. Lautz, and A. Tavakkolizadeh, "Band revision versus Roux-en-Y gastric bypass conversion as salvage operation after laparoscopic adjustable gastric banding," Surgery for Obesity and Related Diseases, vol. 7, no. 1, pp. 33-37, 2011.
 N. V Christou, D. Look, and L. D. MacLean, "Weight gain after short- and long-limb gastric bypass in patients followed for longer than 10 years," Annals of Surgery, vol. 244, no. 5, pp. 734-740, 2006.
 H. Shimizu, S. Annaberdyev, I. Motamarry, M. Kroh, P. Schauer, and S. Brethauer, "Revisional bariatric surgery for unsuccessful weight loss and complications," Obesity Surgery, vol. 23, no. 11, pp. 1766-1773, 2013.
 D. O. Magro, B. Geloneze, R. Delfini, B. C. Pareja, F. Callejas, and J. C. Pareja, "Long-term weight regain after gastric bypass: a 5-year prospective study," Obesity Surgery, vol. 18, no. 6, pp. 648-651, 2008.
 S. Abu-Gazala and A. Keidar, "Conversion of failed gastric banding into four different bariatric procedures," Surgery for Obesity and Related Diseases, vol. 8, no. 4, pp. 400-407, 2012.
 L. Biertho, R. Steffen, R. Branson et al., "Management of failed adjustable gastric banding," Surgery, vol. 137, no. 1, pp. 33-41, 2005.
 B. Snyder, A. Nguyen, T. Scarbourough, S. Yu, and E. Wilson, "Comparison of those who succeed in losing significant excessive weight after bariatric surgery and those who fail," Surgical Endoscopy and Other Interventional Techniques, vol. 23, no. 10, pp. 2302-2306, 2009.
 P. Yimcharoen, H. M. Heneghan, M. Singh et al., "Endoscopic findings and outcomes of revisional procedures for patients with weight recidivism after gastric bypass," Surgical endoscopy, vol. 25, no. 10, pp. 3345-3352, 2011.
 O. Tucker, I. Sucandy, S. Szomstein, and R. J. Rosenthal, "Revisional surgery after failed laparoscopic adjustable gastric banding," Surgeryfor Obesity and Related Diseases, vol. 4, no. 6, pp. 740-747, 2008.
 F. B. Langer, A. Bohdjalian, S. Shakeri-Leidenmuhler, S. F. Schoppmann, J. Zacherl, and G. Prager, "Conversion from sleeve gastrectomy to roux-en-y gastric bypass-indications and outcome," Obesity Surgery, vol. 20, no. 7, pp. 835-840, 2010.
 M. F. Catalano, G. Rudic, A. J. Anderson, and T. Y. Chua, "Weight gain after bariatric surgery as a result of a large gastric stoma: endotherapy with sodium morrhuate may prevent the need for surgical revision," Gastrointestinal Endoscopy, vol. 66, no. 2, pp. 240-245, 2007.
 S. Horgan, G. Jacobsen, G. D. Weiss et al., "Incisionless revision ofpost-Roux-en-Y bypass stomal and pouch dilation: multicenter registry results," Surgeryfor Obesity and Related Diseases, vol. 6, no. 3, pp. 290-295, 2010.
 Bank of Canada, "Rates & Statistics: Inflation Calculator".
 P. T. Katzmarzyk and I. Janssen, "The economic costs associated with physical inactivity and obesity in Canada: an update," Canadian Journal of Applied Physiology, vol. 29, no. 1, pp. 90-115, 2004.
 A. H. Anis, W Zhang, N. Bansback, D. P. Guh, Z. Amarsi, and C. L. Birmingham, "Obesity and overweight in Canada: an updated cost-of-illness study," Obesity Reviews, vol. 11, no. 1, pp. 31-40, 2010.
 Institute of Health Economics, "Bariatric treatments for adult obesity," Edmonton AB: Institute of Health Economics, 2012.
 E. Moffatt, L. G. Shack, G. J. Petz, J. K. Sauve, K. Hayward, and R. Colman, "The cost of obesity and overweight in 2005: a case study of Alberta, Canada," Canadian Journal of Public Health, vol. 102, no. 2, pp. 144-148, 2011.
 J. Cawley and C. Meyerhoefer, "The medical care costs of obesity: an instrumental variables approach," Journal of Health Economics, vol. 31, no. 1, pp. 219-230, 2012.
 A. G. Tsai, D. F. Williamson, and H. A. Glick, "Direct medical cost of overweight and obesity in the USA: a quantitative systematic review," Obesity Reviews, vol. 12, no. 1, pp. 50-61, 2011.
 S. Colagiuri, C. M. Y. Lee, R. Colagiuri et al., "The cost of overweight and obesity in Australia," Medical Journal of Australia, vol. 192, no. 5, pp. 260-264, 2010.
 C. Mehrotra, M. Serdula, T. S. Naimi, L. K. Khan, J. Miller, and W. Dietz, "Population-based study of trends, costs, and complications of weight loss surgeries from 1990 to 2002," Obesity Research, vol. 13, no. 11, pp. 2029-2034, 2005.
 E. Acholonu, E. McBean, I. Court, O. Bellorin, S. Szomstein, and R. J. Rosenthal, "Safety and short-term outcomes of laparoscopic sleeve gastrectomy as a revisional approach for failed laparoscopic adjustable gastric banding in the treatment of morbid obesity," Obesity Surgery, vol. 19, no. 12, pp. 1612-1616, 2009.
 S. Bardsley and G. Hopkins, "Laparoscopic revision of gastric band surgery," ANZ Journal of Surgery, vol. 80, no. 5, pp. 350-353, 2010.
 R. E. Brolin and M. Asad, "Rationale for reversal of failed bariatric operations," Surgeryfor Obesity and Related Diseases, vol. 5, no. 6, pp. 673-676, 2009.
 B. Deylgat, M. D'Hondt, H. Pottel, F. Vansteenkiste, F. Van Rooy, and D. Devriendt, "Indications, safety, and feasibility of conversion of failed bariatric surgeryto Roux-en-Y gastric bypass: a retrospective comparative study with primary laparoscopic Roux-en-Y gastric bypass," Surgical Endoscopy, pp. 1-6, 2012.
 D. F Greenbaum, S. H. Wasser, T. Riley, T. Juengert, J. Hubler, and K. Angel, "Duodenal switch with omentopexy and feeding jejunostomya safe and effective revisional operation for failed previous weight loss surgery," Surgery for Obesity and Related Diseases, vol. 7, no. 2, pp. 213-218, 2011.
 M. W. Hii, A. C. Lake, C. Kenfield, and G. H. Hopkins, "Laparoscopic conversion of failed gastric banding to Roux-en-Y gastric bypass. Short-term follow-up and technical considerations," Obesity Surgery, pp. 1-7, 2012.
 N. A. Jennings, M. Boyle, K. Mahawar, S. Balupuri, and P. K. Small, "Revisional laparoscopic roux-en-Y gastric bypass following failed laparoscopic adjustable gastric banding," Obesity Surgery, vol. 23, no. 7, pp. 947-952, 2013.
 P. Mognol, D. Chosidow, and J.-P. Marmuse, "Laparoscopic sleeve gastrectomy as an initial bariatric operation for high-risk patients: Initial results in 10 patients," Obesity Surgery, vol. 15, no. 7, pp. 1030-1033, 2005.
 M. K. Muller, N. Attigah, S. Wildi et al., "High secondary failure rate of rebanding after failed gastric banding," Surgical Endoscopy and Other Interventional Techniques, vol. 22, no. 2, pp. 448-453, 2008.
 N. T. Nguyen, S. Hohmann, X. M. Nguyen, C. Elliott, and H. Masoomi, "Outcome of laparoscopic adjustable gastric banding and prevalence of band revision and explantation at academic centers: 2007-2009," Surgery for Obesity and Related Diseases, vol. 8, no. 6, pp. 724-727, 2012.
 S. Patel, S. Szomstein, and R. J. Rosenthal, "Reasons and outcomes of reoperative bariatric surgery for failed and complicated procedures (excluding adjustable gastric banding)," Obesity Surgery, vol. 21, no. 8, pp. 1209-1219, 2011.
 P. P. C. Poyck, F. Polat, D. J. Gouma, and W. L. E. M. Hesp, "Is biliopancreatic diversion with duodenal switch a solution for patients after laparoscopic gastric banding failure?" Surgery for Obesity and Related Diseases, vol. 8, no. 4, pp. 393-399, 2012.
 J. E. Roller and D. A. Provost, "Revision of failed gastric restrictive operations to Roux-en-Y gastric bypass: Impact of multiple prior bariatric operations on outcome," Obesity Surgery, vol. 16, no. 7, pp. 865-869, 2006.
 H. Spivak, O. R. Beltran, P. Slavchev, and E. B. Wilson, "Laparoscopic revision from LAP-BAND[R] to gastric bypass," Surgical Endoscopy and Other Interventional Techniques, vol. 21, no. 8, pp. 1388-1392, 2007.
 M. Suter, J. M. Calmes, A. Paroz, and V Giusti, "A 10-year experience with laparoscopic gastric banding for morbid obesity: high long-term complication and failure rates," Obesity Surgery, vol. 16, no. 7, pp. 829-835, 2006.
 W. W te Riele, Y. K. Sze, M. J. Wiezer, and B. van Ramshorst, "Conversion of failed laparoscopic gastric banding to gastric bypass as safe and effective as primary gastric bypass in morbidly obese patients," Surgery for Obesity and Related Diseases, vol. 4, no. 6, pp. 735-739, 2008.
 P. W. van Rutte, J. F Smulders, J. P. de Zoete, and S. W. Nienhuijs, "Indications and short-term outcomes of revisional surgery after failed or complicated sleeve gastrectomy," Obesity Surgery, vol. 22, no. 12, pp. 1903-1908, 2012.
 B. Van Wageningen, F. J. Berends, B. Van Ramshorst, and I. F. M. Janssen, "Revision of failed laparoscopic adjustable gastric
banding to Roux-en-Y gastric bypass," Obesity Surgery, vol. 16, no. 2, pp. 137-141, 2006.
 M. Worni, T. Ostbye, A. Shah et al., "High risks for adverse outcomes after gastric bypass surgery following failed gastric banding: a population-based trend analysis of the united states," Annals of Surgery, vol. 257, no. 2, pp. 279-286, 2013.
 T. Yazbek, N. Safa, R. Denis, H. Atlas, and P. Garneau, "Laparoscopic sleeve gastrectomy (LSG)--a good bariatric option for failed laparoscopic adjustable gastric banding (LAGB): a review of 90 patients," Obesity Surgery, vol. 23, pp. 300-305, 2013.
 J. Zagzag, B. F. Schwack, H. Youn, C. R. Fielding, G. A. Fielding, and M. S. Kurian, "Does adding a lesser-curvature gastrogastric plication suture reduce the need for revision after laparoscopic adjustable gastric band placement?" Surgical Endoscopy and Other Interventional Techniques, vol. 26, no. 2, pp. 514-517, 2012.
 E. Van Dessel, G. Hubens, M. Ruppert, L. Balliu, J. Weyler, and W. Vaneerdeweg, "Roux-en-Y gastric bypass as a re-do procedure for failed restricive gastric surgery," Surgical Endoscopy and Other Interventional Techniques, vol. 22, no. 4, pp. 1014-1018, 2008.
 C. Boza, C. Gamboa, G. Perez et al., "Laparoscopic adjustable gastric banding (LAGB): Surgical results and 5-year follow-up," Surgical Endoscopy and Other Interventional Techniques, vol. 25, no. 1, pp. 292-297, 2011.
 J.-E. Tarride, M. Haq, V H. Taylor et al., "Health status, hospitalizations, day procedures, and physician costs associated with body mass index (BMI) levels in Ontario, Canada," Clinico Economics and Outcomes Research, vol. 4, no. 1, pp. 21-30, 2012.
 I. Janssen, M. Lam, and P. T. Katzmarzyk, "Influence of overweight and obesity on physician costs in adolescents and adults in Ontario, Canada," Obesity Reviews, vol. 10, no. 1, pp. 51-57, 2009.
 P. L. Chin, M. Ali, K. Francis, and P. C. LePort, "Adjustable gastric band placed around gastric bypass pouch as revision operation for failed gastric bypass," Surgery for Obesity and Related Diseases, vol. 5, no. 1, pp. 38-42, 2009.
 M. L. Rawlins, D. Teel II, K. Hedgcorth, and J. P. Maguire, "Revision of Roux-en-Y gastric bypass to distal bypass for failed weight loss," Surgery for Obesity and Related Diseases, vol. 7, no. 1, pp. 45-49, 2011.
 R. E. Brolin and R. P. Cody, "Adding malabsorption for weight loss failure after gastric bypass," Surgical Endoscopy and Other Interventional Techniques, vol. 21, no. 11, pp. 1924-1926, 2007.
 J. Hedberg, S. Gustavsson, and M. Sundbom, "Long-term follow-up in patients undergoing open gastric bypass as a revisional operation for previous failed restrictive procedures," Surgery for Obesity and Related Diseases, vol. 8, no. 6, pp. 696-701, 2012.
 A. Peeters, J. J. Barendregt, F. Willekens et al., "Obesity in adulthood and its consequences for life expectancy: a life-table analysis," Annals of Internal Medicine, vol. 138, no. 1, pp. 24-32, 2003.
 United States Food and Drug Administration, "Questions and answers," The FDA's Obesity Working Group Report.
 R. Padwal, S. Klarenbach, N. Wiebe et al., "Bariatric surgery: a systematic review and network meta-analysis of randomized trials," Obesity Reviews, vol. 12, no. 8, pp. 602-621, 2011.
 S. P. Sussenbach, A. V Padoin, E. N. Silva et al., "Economic benefits of bariatric surgery," Obesity Surgery, vol. 22, no. 2, pp. 266-270, 2012.
 J. S. Monk Jr., N. D. Nagib, and W. Stehr, "Pharmaceutical savings after gastric bypass surgery," Obesity Surgery, vol. 14, no. 1, pp. 13-15, 2004.
 M. A. Maggard, L. R. Shugarman, M. Suttorp et al., "Metaanalysis: Surgical treatment of obesity," Annals of Internal Medicine, vol. 142, no. 7, pp. 547-559, 2005.
 M. Ryou, M. B. Ryan, and C. C. Thompson, "Current status of endoluminal bariatric procedures for primary and revision indications," Gastrointestinal Endoscopy Clinics of North America, vol. 21, no. 2, pp. 315-333, 2011.
 M. A. Khoursheed, I. A. Al-Bader, F. S. Al-Asfar, A. I. Mohammad, M. Shukkur, and H. M. Dashti, "Revision of failed bariatric procedures to Roux-en-Y gastric bypass (RYGB)," Obesity Surgery, vol. 21, no. 8, pp. 1157-1160, 2011.
Caroline E. Sheppard, (1) Erica L. W. Lester, (2) Anderson W. Chuck, (3) Daniel W. Birch, (1) Shahzeer Karmali, (1) and Christopher J. de Gara (4)
(1) Centre for the Advancement of Minimally Invasive Surgery, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada T5H3V9
(2) University of Alberta, Edmonton, AB, Canada T6G 2C9
(3) University of Alberta, Institute of Health Economics, Edmonton, AB, Canada T5J 3N4
(4) Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, 2-590 Edmonton Clinic Health Academy, 11405-87Avenue NW, Edmonton, AB, Canada T6G2C9
Correspondence should be addressed to Christopher J. de Gara; email@example.com
Received 2 August 2013; Accepted 19 November 2013
Academic Editor: Bj0rn Moum
TABLE 1: The literature search for rates of revision by bariatric procedure. Author, location Surgery Weight Timeframe recidivism to weight rate (%) recidivism (months) Abu--Gazala and LAGB 22.2 Keidar , Israel Acholonu et al. LAGB -- -- , United States Ardestani et al. LAGB 24.4 24 , United States Bardsley and LAGB -- -- Hopkins , Australia Biertho et al. , LAGB 17.4 United States Brolin and Asad All -- -- 2009 , United procedures States Brolin and Cody LRYGB -- -- 2007 , United States Christou et al. , LRYGB 18/35 60/120 Canada Deylgat et al. , LAGB/LSG -- -- Belgium Hedberg et al. LAGB -- -- , Sweden Hii et al. , All -- -- Australia procedures/ LAGB Jennings et al. LAGB -- -- , UK Langer et al. , LSG -- -- Austria Magro et al. , LAGB 18.8 24 Brazil Mognol et al. , LAGB -- -- France Muller et al. , LAGB -- -- Switzerland Nguyen et al. , LAGB -- -- United States Patel et al. , All -- -- United States procedures (except LAGB) Poyck et al. , LAGB -- -- Netherlands Roller and Provost LAGB -- -- , United States Shimizu et al. , RYGB 10-20 -- United States Snyder et al. , LAGB/LRYGB 34/5.2 -- United States Spivak et al. , LAGB -- -- United States Suter et al. , LAGB -- -- Switzerland te Riele et al. , LAGB -- -- Netherlands Tucker et al. , LAGB 39 -- United States Van Dessel et al. LSG/LAGB -- -- , Belgium van Rutte et al. LSG -- -- , Netherlands Van Wageningen LAGB -- -- et al. , Netherlands LAGB -- -- Worni et al. , United States LAGB -- -- Yazbek et al. , Canada Yimcharoen et al. RYGB 10-20 60-120 , United States Zagzag et al. , LAGB -- -- United States Author, location Revision surgery Revision rate (%) Abu--Gazala and LSG, LRYGB, Total: 6.6, LSG: Keidar , Israel LBPD--DS, and 2.64, LRYGB: LBPD 2.64, and LBPD--DS: 1.32 Acholonu et al. LSG 2.7 , United States Ardestani et al. LAGB revision 15.3/2.6 , United States (reband or reposition)/LAGB Removal Bardsley and All procedures 13 Hopkins , Australia Biertho et al. , ReLAGB (with Total: 4.7, reLAGB: 2, United States BPD), LAGB LAGB removal: removal (with 0.2, LRYGB) reLAGB--BPD: 0.5, LAGB removal-LRYGB: 1.9 Brolin and Asad All procedures 9.8 2009 , United States Brolin and Cody Distal LRYGB -- 2007 , United States Christou et al. , -- -- Canada Deylgat et al. , LRYGB -- Belgium Hedberg et al. RYGB -- , Sweden Hii et al. , All All procedures: Australia procedures/RYGB 18.4, RYGB: 0.7 Jennings et al. LRYGB 14.6 , UK Langer et al. , LRYGB -- Austria Magro et al. , -- -- Brazil Mognol et al. , LRYGB -- France Muller et al. , LRYGB, LAGB LRYGB: 40, Switzerland reLAGB: 60 of revised LAGB Nguyen et al. , ReLAGB, LAGB ReLAGB: 0.76, United States removal LAGB removal: 0.87 Patel et al. , All procedures 2.5 United States Poyck et al. , BPD-DS -- Netherlands (LRYGB) Roller and Provost LRYGB -- , United States Shimizu et al. , -- -- United States Snyder et al. , -- -- United States Spivak et al. , LRYGB -- United States Suter et al. , All procedures 30.1 Switzerland te Riele et al. , LRYGB 14.1 Netherlands Tucker et al. , -- Total: 16.5, United States LAGB removal: 9.1, LAGB removal-LSG: 3.6, and LAGB removal--LRYGB: 2.3 Van Dessel et al. LRYGB -- , Belgium van Rutte et al. LRYGB 5.5 , Netherlands Van Wageningen LRYGB 7.6 et al. , Netherlands LRYGB 0.6 Worni et al. , United States LSG -- Yazbek et al. , Canada Yimcharoen et al. -- -- , United States Zagzag et al. , All procedures 1.76 United States Author, location Revision rate (weight Timeframe to recidivism) revision (%) (months) Abu--Gazala and -- 36 Keidar , Israel Acholonu et al. -- 34.7 (16-60) , United States Ardestani et al. 84.2 of LAGB Revision in 21.5 , United States revisions (0-49), conversion in 27.6 (11-48) Bardsley and 2.6 3-36 Hopkins , Australia Biertho et al. , -- United States Brolin and Asad 6.6 -- 2009 , United States Brolin and Cody -- -- 2007 , United States Christou et al. , -- -- Canada Deylgat et al. , LAGB: 38.9, -- Belgium LSG: 8.3 Hedberg et al. -- -- , Sweden Hii et al. , -- -- Australia Jennings et al. -- -- , UK Langer et al. , 6.8 33 (15-70) Austria Magro et al. , -- -- Brazil Mognol et al. , 9.4 42 (7-74) France Muller et al. , -- -- Switzerland Nguyen et al. , -- -- United States Patel et al. , -- -- United States Poyck et al. , 17 -- Netherlands Roller and Provost 59.5 of LAGB -- , United States revisions Shimizu et al. , -- -- United States Snyder et al. , -- -- United States Spivak et al. , 1.7 28.2 (11-46) United States Suter et al. , -- -- Switzerland te Riele et al. , 11.4 66.2 (12.7-120) Netherlands Tucker et al. , 7.8 21.8 [+ or -] 13.9 United States (4 days-47 months) Van Dessel et al. 100/50 of 54 , Belgium revisions van Rutte et al. -- 18 (10-21) , Netherlands Van Wageningen 62 54 [+ or -] 22.8 et al. , Netherlands -- -- Worni et al. , United States 57.7 of LAGB -- Yazbek et al. , revisions Canada Yimcharoen et al. -- -- , United States Zagzag et al. , -- -- United States Author, location Complication 2nd revision rate (%) surgery Abu--Gazala and -- -- Keidar , Israel Acholonu et al. -- -- , United States Ardestani et al. Revision 4.3, LAGB , United States conversion 10.5 revision/reLAGB- RYGB Bardsley and -- -- Hopkins , Australia Biertho et al. , ReLAGB: 8.1, -- United States LAGB removal-LRYGB: 6.3, ReLAGB-BPD: 25.3 Brolin and Asad 33 -- 2009 , United States Brolin and Cody 18.5 -- 2007 , United States Christou et al. , -- -- Canada Deylgat et al. , -- -- Belgium Hedberg et al. 8 -- , Sweden Hii et al. , Equivalent rate -- Australia to primary surgery Jennings et al. -- -- , UK Langer et al. , -- -- Austria Magro et al. , -- -- Brazil Mognol et al. , 14.3 -- France Muller et al. , -- ReLAGB, LAGB Switzerland removal--LRYGB, and distal LRYGB Nguyen et al. , 18.8 -- United States Patel et al. , -- -- United States Poyck et al. , -- -- Netherlands Roller and Provost -- 2nd revision: 29.6, , United States multiple revisions: 41.7 Shimizu et al. , -- -- United States Snyder et al. , -- -- United States Spivak et al. , -- -- United States Suter et al. , -- -- Switzerland te Riele et al. , Equivalent rate revision due to Netherlands to primary (29.6 complications, none versus 30.9) for weight gain Tucker et al. , 15.2 2nd revision/3rd United States revision/4th and 5th Van Dessel et al. -- -- , Belgium van Rutte et al. -- , Netherlands Van Wageningen Equivalent rate -- et al. , to primary Netherlands 3.7 -- Worni et al. , United States 5.5 -- Yazbek et al. , Canada Yimcharoen et al. -- -- , United States Zagzag et al. , -- -- United States Author, location Timeframe to 2nd revision 2nd revision (months) rate (%) Abu--Gazala and -- -- Keidar , Israel Acholonu et al. -- -- , United States Ardestani et al. -- LAGB revision: , United States 22.6, reLAGB- RYGB: 5.3 Bardsley and -- -- Hopkins , Australia Biertho et al. , -- -- United States Brolin and Asad -- -- 2009 , United States Brolin and Cody -- -- 2007 , United States Christou et al. , -- -- Canada Deylgat et al. , -- -- Belgium Hedberg et al. -- -- , Sweden Hii et al. , -- -- Australia Jennings et al. -- -- , UK Langer et al. , -- -- Austria Magro et al. , -- -- Brazil Mognol et al. , -- -- France Muller et al. , -- ReLAGB: 45 Switzerland (25 for weight), LAGB removal- LRYGB: 2.2, and distal LRYGB: 20 (13 for weight) Nguyen et al. , -- -- United States Patel et al. , -- -- United States Poyck et al. , -- -- Netherlands Roller and Provost -- -- , United States Shimizu et al. , -- -- United States Snyder et al. , -- -- United States Spivak et al. , -- -- United States Suter et al. , -- -- Switzerland te Riele et al. , -- 20 Netherlands Tucker et al. , 13.2 (3 20/7.5/2.5 United States days-44.7 months)/21.2 (12--28.5) Van Dessel et al. -- -- , Belgium van Rutte et al. -- -- , Netherlands Van Wageningen -- -- et al. , Netherlands -- -- Worni et al. , United States -- -- Yazbek et al. , Canada Yimcharoen et al. -- -- , United States Zagzag et al. , -- -- United States
|Printer friendly Cite/link Email Feedback|
|Author:||Sheppard, Caroline E.; Lester, Erica L.W.; Chuck, Anderson W.; Birch, Daniel W.; Karmali, Shahzeer;|
|Publication:||Gastroenterology Research and Practice|
|Date:||Jan 1, 2014|
|Previous Article:||Endoscopic optical coherence tomography (OCT): advances in gastrointestinal imaging.|
|Next Article:||Aberrant MicroRNAs in pancreatic cancer: researches and clinical implications.|